HB 57 revises Florida’s controlled-substances laws to specifically address xylazine, a veterinary drug that has been increasingly associated with illicit drug mixtures. The bill removes certain FDA-approved xylazine animal drug products used as directed from Schedule I, while making clear that xylazine intended for human use remains outside that exception. It also adds xylazine to the list of substances covered by Florida’s criminal drug laws and creates a new trafficking offense for xylazine.
The bill establishes felony penalties for selling, manufacturing, delivering, or possessing with intent to sell, manufacture, or deliver xylazine, and it sets mandatory minimum prison terms for trafficking based on quantity. In addition to xylazine-specific changes, the bill amends Florida’s existing drug-trafficking statutes to add xylazine to the state’s most serious controlled-substance enforcement framework, alongside fentanyl and other high-risk drugs. The bill also includes a separate enhancement for certain fentanyl-related offenses when the substance is packaged or presented in a way that resembles candy, cereal, gummies, vitamins, or branded food products, or uses cartoon-character imagery.
More broadly, HB 57 expands and updates Florida’s Schedule I controlled-substance list and related definitions to capture a wide range of synthetic cannabinoids, cathinones, phenethylamines, tryptamines, and other designer drugs. The bill is written in a broad, class-based way that is intended to cover current and emerging variants of these substances, not just the named examples. It also preserves exceptions for approved pharmaceutical products and certain FDA-authorized animal drug products.
The bill’s impact on state law would be significant for law enforcement, prosecutors, courts, and regulated veterinary or pharmaceutical users of xylazine. It would create a new standalone trafficking offense for xylazine, increase penalties for certain xylazine distribution offenses, and integrate xylazine into Florida’s existing mandatory-minimum sentencing structure. It would also broaden the state’s controlled-substance schedules and trafficking provisions to reach additional synthetic drugs and analogues, potentially increasing criminal exposure for possession, sale, manufacture, importation, and delivery of those substances.
No committee transcripts or recorded votes were provided, and the bill ultimately died in returning messages. Based on the bill text alone, the measure appears to have been framed as a public-safety and drug-enforcement bill, with an emphasis on combating illicit xylazine and fentanyl mixtures. The main point of contention likely would have been the breadth of the criminal penalties and the scope of the synthetic-drug scheduling language, especially for veterinary, pharmaceutical, and analog-based substances.
HB 57 would amend Florida Statutes sections 893.03, 893.13, and 893.135 to add xylazine to the state’s controlled-substance framework, exempt certain FDA-approved xylazine animal drug products from Schedule I, and create new criminal penalties and trafficking thresholds for xylazine. It would also expand trafficking and scheduling provisions for numerous synthetic cannabinoids, cathinones, phenethylamines, tryptamines, and related designer drugs, while adding a packaging-based enhancement for certain fentanyl offenses. The bill would increase mandatory minimum sentences and fines for covered conduct and would affect law enforcement, prosecutors, defendants, veterinarians, and pharmaceutical/animal-drug users.
No committee discussion or vote history is available, so there is no recorded debate to summarize. The bill’s text suggests a strong enforcement-oriented approach aimed at curbing illicit drug distribution, particularly xylazine and fentanyl mixtures. Its failure to advance indicates that, whatever support it may have had, it did not complete the legislative process.
The most likely points of contention are the bill’s broad criminalization and mandatory minimum sentencing provisions, especially the new trafficking offense for xylazine and the enhanced penalties tied to packaging that resembles candy or branded consumer products. Another likely area of concern is the bill’s expansive class-based scheduling of synthetic cannabinoids and other designer drugs, which could raise questions about overbreadth, enforcement complexity, and impacts on legitimate veterinary or pharmaceutical uses. Supporters would likely emphasize overdose prevention and drug-enforcement tools, while critics would likely focus on sentencing severity and the breadth of the controlled-substance definitions.